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A commentary on
Ubiquitin is phosphorylated by PINK1 to
activate parkin
by Koyano F, Okatsu K, Kosako H,
Tamura Y, Go E, Kimura M, et al.
Nature (2014) 510(7503):162–6. doi:10.
1038/nature13392
Mutations in PARK2, a gene encoding
cytosolic E3 ubiquitin ligase parkin cause
autosomal recessive Parkinsonism simi-
lar to mutations in the less prevalent
PINK1 (PTEN induced putative kinase
1). Parkin and PINK 1 (Ser/Thr kinase)
eliminate damaged mitochondria through
mitophagy and mutations cause accumula-
tion of impaired mitochondria and reactive
oxygen species (1). PINK1, when activated
by depolarization of the mitochondrial
membrane potential, leads to phospho-
rylation and activation of E3 parkin lig-
ase [Okatsu (2)]. PINK1 acts upstream to
parkin accelerating latent E3 parkin activity
and increasing accumulation of parkin on
depolarized mitochondria in Drosophila.
Presumably, PINK1-dependent phospho-
rylation of parkin at Ser65 accelerates E3
parkin activity. However, the substrate for
PINK 1 phosphorylation of parkin has
remained elusive.
Koyano et al. (1) demonstrated that
PINK1 phosphorylates ubiquitin, which
subsequently activates parkin on dam-
aged mitochondria. PINK1-dependent
parkin activation proceeds in two phases:
phosphorylation of ubiquitin-like (UBL)
domain of parkin at Ser 65, followed by
phosphorylation at Ser 65 of ubiquitin
itself. While UBL domain is known for
keeping parkin inactivated, phosphoryla-
tion of Ser 65 activates parkin partially
(3). Autoubiquitination is not promoted
by non-phosphorylated ubiquitin. Kane
et al. (4) and Kazlauskaite et al. (3) also
confirmed phosphorylated ubiquitin as a
parkin activator. These studies shed light
on two further PINK1/parkin metabolism
issues: (1) why does a phosphorylation-
deficient mutation of parkin inhibit forma-
tion of a ubiquitin-ester (an intermediate
product in the parkin activation pathway),
(2) why does a phosphomimetic parkin
mutant still require PINK1 for activation.
Koyano et al. used phosphate affinity
(phos-tag) PAGE assay to identify a slower-
migrating ubiquitin band, phosphorylated
by PINK1 on damaged mitochondria (i.e.,
pre-treated a protonophore). Mass spec-
trometry analysis identified Ser 65 as the
ubiquitin phosphorylation site. A yeast sys-
tem was used to confirm that phospho-
rylated ubiquitin at Ser 65 is a parkin
activator. Thus, ubiquitin acts not only as
a substrate for phosphorylation but also
activates parkin itself.
Koyano et al. proposed that parkin is
fully activated by repression of the cat-
alytic cysteine by RING0 domain unlocked
by phosphorylated ubiquitin and UBL
domain.
Parkinson’s disease is an incurable neu-
rodegenerative condition. Defects in mito-
chondrial regulation have been implicated
as one of the key elements in the etiol-
ogy of parkinsonism. PINK 1 and parkin
act as neuroprotective agents by maintain-
ing mitochondrial homeostasis. Decreased
antioxidant effect may be seen in other seri-
ous disorders, such as tumors where parkin
expression is frequently diminished (5).
Mechanism of interaction between these
two proteins has been unclear. Koyano et al.
used a yeast system to aid demonstration of
the important role of phosphorylated ubiq-
uitin acting as a long-searched for mediator
between PINK1 and parkin.
The above results may lead to novel
therapeutic options for Parkinson’s disease.
Cornelissen et al. (6) proposed a treat-
ment strategy based upon inhibition of
ubiquitin-specific protease 15 (USP15), a
deubiquitinating enzyme (DUB) counter-
acting Parkin-mediated autophagy, while
Kazlauskaite et al. (3) suggested develop-
ment of a parkin activator in the form of
ubiquitin-like agent.
PINK1 driven phosphorylation of ubiq-
uitin has important implications in under-
standing the underlying pathophysiologi-
cal mechanisms of parkinsonism and to
develop new treatment strategies for an
incurable movement disorder.
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